NASDAQ:SNNA opened at $6.31 on Monday. The stock has a market cap of $213.73 million, a PE ratio of -1.22 and a beta of 1.56. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.67. Sienna Biopharmaceuticals has a 1-year low of $5.53 and a 1-year high of $25.71.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.79) by ($0.03). As a group, sell-side analysts anticipate that Sienna Biopharmaceuticals will post -2.95 earnings per share for the current year.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Story: Understanding each part of a balance sheet
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.